Thomas Stiermaier1,2, Janine Pöss1,2, Charlotte Eitel1,2, Suzanne de Waha1,2, Georg Fuernau1,2, Steffen Desch3, Holger Thiele3, Ingo Eitel4,5. 1. Medical Clinic II (Cardiology/Angiology/Intensive Care Medicine), University Heart Center Lübeck, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Germany. 2. German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany. 3. Department of Internal Medicine/Cardiology, Heart Center Leipzig-University Hospital, Leipzig, Germany. 4. Medical Clinic II (Cardiology/Angiology/Intensive Care Medicine), University Heart Center Lübeck, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Germany. ingo.eitel@uksh.de. 5. German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany. ingo.eitel@uksh.de.
Abstract
BACKGROUND:Left ventricular hypertrophy (LVH) has been suggested as a determinant of outcome in patients with ST-segment elevation myocardial infarction (STEMI). However, available data are inconclusive and the underlying mechanisms remain unclear. Therefore, the aim of this study was to evaluate the impact of LVH on myocardial injury and clinical outcome in a large multicenter STEMI population. METHODS:Cardiovascular magnetic resonance was performed in 795 patients within 10 days after STEMI to assess left ventricular (LV) mass and parameters of myocardial injury. Gender-specific cutoff values of indexed LV mass were used to define LVH (67 g/m2 for men and 61 g/m2 for women). Rates of major adverse cardiac events (MACE) were determined at 12-month follow-up. RESULTS:LVH was present in 438 patients (55%) and associated with a significantly larger infarct size [18.3% of LV mass (%LV) versus 14.0%LV; p < 0.01], a lower myocardial salvage index (47.8 versus 54.4; p < 0.01), larger extent of microvascular obstruction (0.4 versus 0%LV; p < 0.01) and lower LV ejection fraction (47.9 versus 53.2%; p < 0.01) compared to STEMI patients without LVH. The effect of LVH on LV ejection fraction, infarct size and myocardial salvage index remained statistically significant after adjustment for baseline characteristics (p < 0.01 for all). MACE rates at 12 months were numerically higher in patients with versus without LVH without reaching statistical significance (7.5 versus 5.6%; p = 0.32). CONCLUSION: In STEMI patients, LVH is associated with more pronounced structural and functional alterations in CMR imaging as an indicator for adverse clinical outcomes in STEMI survivors.
RCT Entities:
BACKGROUND:Left ventricular hypertrophy (LVH) has been suggested as a determinant of outcome in patients with ST-segment elevation myocardial infarction (STEMI). However, available data are inconclusive and the underlying mechanisms remain unclear. Therefore, the aim of this study was to evaluate the impact of LVH on myocardial injury and clinical outcome in a large multicenter STEMI population. METHODS: Cardiovascular magnetic resonance was performed in 795 patients within 10 days after STEMI to assess left ventricular (LV) mass and parameters of myocardial injury. Gender-specific cutoff values of indexed LV mass were used to define LVH (67 g/m2 for men and 61 g/m2 for women). Rates of major adverse cardiac events (MACE) were determined at 12-month follow-up. RESULTS: LVH was present in 438 patients (55%) and associated with a significantly larger infarct size [18.3% of LV mass (%LV) versus 14.0%LV; p < 0.01], a lower myocardial salvage index (47.8 versus 54.4; p < 0.01), larger extent of microvascular obstruction (0.4 versus 0%LV; p < 0.01) and lower LV ejection fraction (47.9 versus 53.2%; p < 0.01) compared to STEMI patients without LVH. The effect of LVH on LV ejection fraction, infarct size and myocardial salvage index remained statistically significant after adjustment for baseline characteristics (p < 0.01 for all). MACE rates at 12 months were numerically higher in patients with versus without LVH without reaching statistical significance (7.5 versus 5.6%; p = 0.32). CONCLUSION: In STEMI patients, LVH is associated with more pronounced structural and functional alterations in CMR imaging as an indicator for adverse clinical outcomes in STEMI survivors.
Entities:
Keywords:
Cardiac magnetic resonance imaging; Left ventricular hypertrophy; Myocardial injury; Prognosis; ST-segment elevation myocardial infarction
Authors: Anil Verma; Alessandra Meris; Hicham Skali; Jalal K Ghali; J Malcolm O Arnold; Mikhail Bourgoun; Eric J Velazquez; John J V McMurray; Lars Kober; Marc A Pfeffer; Robert M Califf; Scott D Solomon Journal: JACC Cardiovasc Imaging Date: 2008-09
Authors: Michel G Khouri; Ronald M Peshock; Colby R Ayers; James A de Lemos; Mark H Drazner Journal: Circ Cardiovasc Imaging Date: 2010-01-08 Impact factor: 7.792
Authors: Oliver Turschner; Jan D'hooge; Christoph Dommke; Piet Claus; Erik Verbeken; Ivan De Scheerder; Bart Bijnens; George R Sutherland Journal: Eur Heart J Date: 2004-05 Impact factor: 29.983
Authors: Teresa S M Tsang; Marion E Barnes; Bernard J Gersh; Yasuhiko Takemoto; A Gabriela Rosales; Kent R Bailey; James B Seward Journal: J Am Coll Cardiol Date: 2003-10-01 Impact factor: 24.094
Authors: John F Younger; Sven Plein; Julian Barth; John P Ridgway; Stephen G Ball; John P Greenwood Journal: Heart Date: 2007-05-31 Impact factor: 5.994
Authors: Nadine Kawel-Boehm; Alicia Maceira; Emanuela R Valsangiacomo-Buechel; Jens Vogel-Claussen; Evrim B Turkbey; Rupert Williams; Sven Plein; Michael Tee; John Eng; David A Bluemke Journal: J Cardiovasc Magn Reson Date: 2015-04-18 Impact factor: 5.364
Authors: Martin Reindl; Christina Tiller; Magdalena Holzknecht; Ivan Lechner; Dorothea Eisner; Laura Riepl; Mathias Pamminger; Benjamin Henninger; Agnes Mayr; Johannes P Schwaiger; Gert Klug; Axel Bauer; Bernhard Metzler; Sebastian J Reinstadler Journal: Clin Res Cardiol Date: 2020-04-15 Impact factor: 5.460
Authors: Edward T Ha; Marc Cohen; Theodore J Gaeta; Manish A Parikh; Stephen J Peterson; Wilbert S Aronow Journal: Arch Med Sci Atheroscler Dis Date: 2021-07-19
Authors: Piotr Szolc; Łukasz Niewiara; Paweł Kleczyński; Krzysztof Bryniarski; Elżbieta Ostrowska-Kaim; Kornelia Szkodoń; Piotr Brzychczy; Krzysztof Żmudka; Jacek Legutko; Bartłomiej Guzik Journal: J Cardiovasc Dev Dis Date: 2022-08-26